On March 28, Novo Nordisk reached a licensing agreement with biopharmaceutical company Lexicon Pharmaceuticals, under which Novo Nordisk will obtain the global development, production and commercialization rights of Lexicon's LX9851, a drug for the treatment of obesity and related metabolic disorders. The deal is worth up to $1 billion and is Novo Nordisk's second weight loss drug deal this week. On Monday, Novo Nordisk acquired the global rights to China Federal Pharmaceutical's weight loss drug for up to $2 billion.